Immunetrics and Eli Lilly extend collaboration

The collaboration expands on a previously announced project in which the companies sought to validate the use of Immunetrics in silico models of inflammation in predicting the outcomes of clinical trials and in optimizing the design of a clinical study. Following this demonstration, the further collaboration will expand the scope of clinical trial design activity.

Certain results of the initial collaboration were jointly presented by Immunetrics and Lilly at the June 2006 conference of the Shock Society. The presentation described the development of a system of nonlinear differential equations describing the time course of immune response and coagulation in sepsis, including the effects of trauma and surgery.

While a typical simulated trial size involved 40,000 subjects, the total number of subjects simulated over the course of the initial collaboration exceeded 1.4 million.

The simulated clinical trial predicted 28-day mortality well within the limits of statistical error. The simulated clinical trial also accurately predicted the actual results in most subgroups divided according to age and the presence or absence of surgery.